Sponsored Links
| Three Rivers Pharmaceuticals Announces FDA Approval Of Expanded Labeling Of INFERGEN(R) |
 |
 |
 |
| Medical News - Liver Disease and Hepatitis | |||
|
Three Rivers Pharmaceuticals, LLC, received expanded labeling from the U.S. Food and Drug Administration (FDA) to include daily use of INFERGEN (Consensus Interferon) in combination with ribavirin (RBV) for retreatment of chronic hepatitis C patients. The expanded labeling targets hepatitis C patients who need retreatment... Read more: Liver Disease / Hepatitis News From Medical News Today
|